Tenaya raises about $53M; BeiGene’s PD-1 gets a first-line approval
Plus, news about Evotec and Osivax:
Tenaya Therapeutics’ $52.5M public offering: The heart disease specialist intends to spend the proceeds from its
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
